Evaluation of effects of Rosuvastatin 40mg on Myocardial Ischemia in subjects with coronary artery disease

Study identifier:4522IL/0043

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An 8-week randomized double blind placebo controlled multicenter trial to evaluate the effects of Rosuvastatin 40mg on Myocardial Ischemia in subjects with coronary artery disease.

Medical condition

Myocardial ischaemia

Phase

Phase 3

Healthy volunteers

Study drug

Rosuvastatin

Sex

All

Actual Enrollment

280

Study type

Interventional

Age

18 Years - 150 Years

Date

Study Start Date: 01 Dec 2001

Primary Completion Date: -

Study Completion Date: 01 Dec 2002

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Mar 2009 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions
Experimental: 1 Rosuvastatin	-
No Intervention: 2 Diet	-

Documents available

Trial Results Summaries
Available here

Contacts

Contact

null AstraZeneca Clinical Study Information

800-236-9933

[email protected]

Investigators

Principal Investigator

Michael Cressman

AstraZeneca